• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Guidelines for the use of palivizumab in infants and young children with congenital heart disease.

作者信息

Nakazawa Makoto, Saji Tsutomu, Ichida Fukiko, Oyama Kotaro, Harada Kensuke, Kusuda Satoshi

机构信息

Guideline Preparation and Review Committee, Heart Institute of Japan, Tokyo Women's Medical University, Tokyo, Japan.

出版信息

Pediatr Int. 2006 Apr;48(2):190-3. doi: 10.1111/j.1442-200X.2006.02179.x.

DOI:10.1111/j.1442-200X.2006.02179.x
PMID:16635185
Abstract
摘要

相似文献

1
Guidelines for the use of palivizumab in infants and young children with congenital heart disease.先天性心脏病婴幼儿使用帕利珠单抗的指南。
Pediatr Int. 2006 Apr;48(2):190-3. doi: 10.1111/j.1442-200X.2006.02179.x.
2
Palivizumab in congenital heart disease: should international guidelines be revised?
Expert Opin Biol Ther. 2007 Nov;7(11):1615-20. doi: 10.1517/14712598.7.11.1615.
3
Re: recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.关于：使用帕利珠单抗预防先天性心脏病婴儿呼吸道合胞病毒感染的建议。
Cardiol Young. 2004 Aug;14(4):466-7; author reply 467-9. doi: 10.1017/S1047951104244225.
4
Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.日本先天性心脏病患儿使用帕利珠单抗预防呼吸道合胞病毒的全国性调查。
Pediatr Infect Dis J. 2008 Dec;27(12):1108-9. doi: 10.1097/INF.0b013e3181801d76.
5
Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.优化先天性心脏病患儿新型单克隆抗体的给药与使用：一项成功的省级呼吸道合胞病毒预防计划。
Can J Cardiol. 2007 May 1;23(6):463-6. doi: 10.1016/s0828-282x(07)70785-7.
6
Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.帕利珠单抗与先天性心脏病患儿呼吸道合胞病毒疾病的预防
Expert Opin Biol Ther. 2007 Sep;7(9):1471-80. doi: 10.1517/14712598.7.9.1471.
7
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.帕利珠单抗预防可降低患有血流动力学显著先天性心脏病的幼儿因呼吸道合胞病毒感染导致的住院率。
J Pediatr. 2003 Oct;143(4):532-40. doi: 10.1067/s0022-3476(03)00454-2.
8
Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.关于使用帕利珠单抗预防先天性心脏病婴儿呼吸道合胞病毒感染的建议。
Cardiol Young. 2003 Oct;13(5):420-3.
9
Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.对29至32周龄早产儿呼吸道合胞病毒相关住院情况及帕利珠单抗使用情况的观察性研究。
Eur J Clin Microbiol Infect Dis. 2006 Feb;25(2):120-2. doi: 10.1007/s10096-005-0082-y.
10
[Prevention of respiratory syncytial virus infections with palivizumab].[使用帕利珠单抗预防呼吸道合胞病毒感染]
Tidsskr Nor Laegeforen. 2003 Apr 3;123(7):941-3.

引用本文的文献

1
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults.一项评估呼吸道合胞病毒中和单克隆抗体 MK-1654 在健康日本成年人中的安全性、药代动力学和药效学的 I 期研究。
Clin Transl Sci. 2022 Jul;15(7):1753-1763. doi: 10.1111/cts.13290. Epub 2022 May 17.
2
Detection of the Onset of the Epidemic Period of Respiratory Syncytial Virus Infection in Japan.日本呼吸道合胞病毒感染流行期起始的检测
Front Public Health. 2019 Mar 7;7:39. doi: 10.3389/fpubh.2019.00039. eCollection 2019.
3
Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan.
帕利珠单抗预防免疫功能低下或唐氏综合征儿童呼吸道合胞病毒感染：日本的一项多中心上市后监测
Paediatr Drugs. 2018 Feb;20(1):97-104. doi: 10.1007/s40272-017-0264-y.
4
Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection.呼吸道合胞病毒：血清型和基因型变异对感染临床过程的影响。
Int J Mol Sci. 2017 Aug 6;18(8):1717. doi: 10.3390/ijms18081717.
5
Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses.根据特定先天性心脏病诊断结果，一岁儿童第二年因呼吸道合胞病毒住院的风险。
PLoS One. 2017 Mar 2;12(3):e0172512. doi: 10.1371/journal.pone.0172512. eCollection 2017.
6
Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease.确定先天性心脏病婴儿中重症呼吸道合胞病毒感染的风险及相关发病率和死亡率。
Infect Dis Ther. 2017 Mar;6(1):37-56. doi: 10.1007/s40121-016-0142-x. Epub 2017 Jan 9.
7
Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.帕利珠单抗在因呼吸道合胞病毒感染而有严重疾病高风险的儿童中的安全性和有效性：系统评价。
Infect Dis Ther. 2014 Dec;3(2):133-58. doi: 10.1007/s40121-014-0046-6. Epub 2014 Oct 9.